Bilimsel çalışmalar

Doç. Dr. Nalan Akgül Babacan

63 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Ozkan, K., Turkkan, E., Ender, K., Mutlu, D., Murat, A., Nalan, B., A Yıldız, Osman, M. (2005). 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients. Indian Journal of cancer, 42(2), 85.

    Kaynak: medicana.com.tr profil sayfası

  2. Odabas, H., Ozdemir, N., Isik, M., Abali, H., Oksuzoglu, B., Kos, T., B. Civelek, A.N. Babacan, U. Dogan, Zengin, N. (2010). Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. Journal of BU ON: official journal of the Balkan Union of Oncology, 16(3), 460-463.

    Kaynak: medicana.com.tr profil sayfası

  3. Cihan, S., Uncu, D., Babacan, N. A., Özdemir, N., Odabaş, H., Aksoy, S.,Oksuzoglu B, Zengin, N. (2011). Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma. Asian Pac J Cancer Prev, 12(4), 967-970.

    Kaynak: medicana.com.tr profil sayfası

  4. Kesikli, S. A., Eren, M. F., Akgul Babacan, N., & Kilickap, S. (2012). Prognosis of colorectal cancer with peritoneal carcinomatosis: Is a new staging necessary? Journal of Clinical Oncology, 30(18), 2287-2288.

    Kaynak: medicana.com.tr profil sayfası

  5. Babacan, N. A., Aksoy, S., Cetin, B., Ozdemir, N. Y., Benekli, M., Uyeturk, U., M. Ali Kaplan, T. Kos, H. Karaca, B. Oksuzoglu, N. Zengin, S. Buyukberber (2012). Multiple primary malignant neoplasms: Multi-center results from Turkey. J BUON, 17(4), 770-5.

    Kaynak: medicana.com.tr profil sayfası

  6. Demirci, U., Ozdemir, N., Benekli, M., Babacan, N. A., Cetin, B., Baykara, M., U. Coskun, N. Zengin, Buyukberber, S. (2012). Lymphoproliferative disorders in multiple primary cancers. Asian Pacific Journal of Cancer Prevention, 13(1), 383-386.

    Kaynak: medicana.com.tr profil sayfası

  7. Budakoğlu, B., Aksoy, S., Arslan, Ç., Üyetürk, Ü., Babacan, N. A., Özcan, M. F., Ozcan, R. Yıldız, B.B. Oven, N.Y. Ozdemir, O. Dizdar, Büyükberber, S. (2012). Frequency of HCV infection in renal cell carcinoma patients. Medical Oncology, 29(3), 1892-1895.

    Kaynak: medicana.com.tr profil sayfası

  8. Seker, M. M., Sancaktar, E., Acibucu, D. O., Filiz, A. K., Deveci, K., Bahceci, A., Kaçan T, Babacan N, Yuce, S. (2013). Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients. Eur Rev Med Pharmacol Sci, 17(21), 2929-2932.

    Kaynak: medicana.com.tr profil sayfası

  9. Babacan, N. A., Yucel, B., Kilickap, S., Seker, M. M., Kacan, T., Olcas, I. K., Eren A.A., Odabas, H. (2013). Lung cancer in women: a single institution experience with 50 patients. Asian Pacific journal of cancer prevention: APJCP, 15(1), 151-154.

    Kaynak: medicana.com.tr profil sayfası

  10. Yucel, B., Babacan, N. A., Kacan, T., Eren, A. A., Eren, M. F., Bahar, S., Celasun, M. G., Seker M.M, Hasbek, Z. (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pacific Journal of Cancer Prevention, 14(11), 6687-6692.

    Kaynak: medicana.com.tr profil sayfası

  11. Bilici, A., Inanc, M., Ulas, A., Akman, T., Seker, M., Babacan N. A., A. İnal, , Bal O., Koral L., Sevinç A., Tufan G., Elkıran E.T., Oven Ustaalioglu B.B., Yavuzsen T., Alkıs N., Ozkan M., Gumus M.. (2013). Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology. Asian Pacific Journal of Cancer Prevention, 14(11), 6493-6499.

    Kaynak: medicana.com.tr profil sayfası

  12. Yetisyigit, T., Babacan, N., Urun, Y., Seber, E. S., Cihan, S., Arpaci, E., N. Yıldırım, S. Aksoy, B. Budakoglu, N. Zengin, B. Oksuzoglu, B. Cicek Yalcın, N. Alkis, (2014). Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors. Asian Pac J Cancer Prev, 15(2), 831-5.

    Kaynak: medicana.com.tr profil sayfası

  13. Kacan, T., Babacan, N. A., Seker, M., Yucel, B., Bahceci, A., Eren, Eren A. A., Eren M.F., Kılıckap S. (2014). Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers. Asian Pac J Cancer Prev, 15(5), 2089-2094.

    Kaynak: medicana.com.tr profil sayfası

  14. Kilickap, S., Kaya, Y., Yucel, B., Tuncer, E., Babacan, N. A., & Elagoz, S. (2014). Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev, 15(3), 1381-1385.

    Kaynak: medicana.com.tr profil sayfası

  15. Kacan, T., Altun, A., Altun, G. G., Kacan, S. B., Sarac, B., Seker M. M., Bahceci A, Babacan, N. (2014). Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells. Asian Pac. J. Cancer Prev, 15(7), 3185-3189.

    Kaynak: medicana.com.tr profil sayfası

  16. Seker, M. M., Yucel, B., Seker, A., Eren, A. A., Bahar, S., Celasun, G.,Kacan T, Eren M.F., Babacan N, Bahceci, A. (2014). Treatment and prognosis of breast cancer in elderly: Different from young patients?. European Geriatric Medicine, 5(4), 261-264.

    Kaynak: medicana.com.tr profil sayfası

  17. Yucel, B., Akkaş, E. A., Okur, Y., Eren, A. A., Eren, M. F., Karapınar, H.,Akgul Babacan N, Kılıçkap, S. (2014). The impact of radiotherapy on quality of life for cancer patients: a longitudinal study. Supportive Care in Cancer, 22(9), 2479-2487.

    Kaynak: medicana.com.tr profil sayfası

  18. Seker, M. M., Sancakdar, E., Seker, A., Bahceci, A., Kacan, T., Babacan, N., S Yuce (2014). Prognostic value of serum TIE-2 and vascular endothelial growth factor levels in gastric cancer patients. (2014): e15085-e15085.

    Kaynak: medicana.com.tr profil sayfası

  19. Seker, M. M., Uslu, A. U., Ozer, H., Seker, A., Kacan, T., Babacan. N.,Aker H, Elagoz, S. (2014). Orbital metastasis of endocervical stromal sarcoma: a rare tumor and an uncommon metastasis. Przeglad menopauzalny= Menopause review, 13(6), 356.

    Kaynak: medicana.com.tr profil sayfası

  20. Yücel, B., Bahar, S., Kaçan, T., Seker, M. M., & Celasun, M. G. Bahceci A., Akgul Babacan N (2014). Importance of metastasis site in survival of patients with breast cancer. Austin J Med Oncol, 1(2), 7.

    Kaynak: medicana.com.tr profil sayfası

  21. Cihan, S., Atasoy, A., Yildirim, Y., Babacan N. A., Kos, T. F. (2014). Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?. Tumori, 101(2), e40-5.

    Kaynak: medicana.com.tr profil sayfası

  22. Cihan, S., Odabas, H., Ozdemir, N. Y., Yazilitas, D., Babacan, N. A. (2015). Treatment Approaches in 102 Elderly Patients With Non-Small Cell Lung Cancer. World Journal of Oncology, 6(1), 276-282

    Kaynak: medicana.com.tr profil sayfası

  23. Babacan, N. A., Kiliçkap, S., Sene, S., Kacan, T., Yucel, B., Eren, M. F., Cihan, S. (2015). A case of multifocal skin metastases from lung cancer presenting with vasculitic-type cutaneous nodule. Indian journal of dermatology, 60(2), 213

    Kaynak: medicana.com.tr profil sayfası

  24. Seker, M. M., Deveci, K., Seker, A., Sancakdar, E., Yilmaz, A., Turesin, A. K.,Kacan T, Babacan, N. A. (2015). Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. Asian Pac J Cancer Prev, 16, 407-410.

    Kaynak: medicana.com.tr profil sayfası

  25. Yilmaz, M., Donmez, G., Kacan, T., Sari, I., Babacan N. A., Sari, M., Kilickap, S. (2015). Significant association between polymorphisms of Wnt antagonist genes and lung cancer. Journal of Investigative Medicine, 63(8), 935-941.

    Kaynak: medicana.com.tr profil sayfası

  26. Tanrıkulu Sımsek E., Besiroglu M., Aktas B., Koca S., Halil Suleyman, Alan O., Hasanov R., Akgul Babacan N., Ozturk MA, Kaya S., Ozdogan OC, Dane F., Yumuk PF (2015). Can we restart vemurafenib after severe hepatotoxicity? A case report. JJ Gastro Hepato, 2(4):025.

    Kaynak: medicana.com.tr profil sayfası

  27. Turan, N., Benekli, M., Unal, O. U., Unek, İ. T., Tastekin, D., Dane, F.,Algın E., Ulger S., Eren T., Ozturk Topcu T., Turkmen E., Akgul Babacan N ... & Buyukberber S. (2015) Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chinese Journal of Cancer Research, 27(4), 408.

    Kaynak: medicana.com.tr profil sayfası

  28. Salman, A., Tekin, B., Koca, S., Babacan, N. A., Yumuk, P. F., Ergun, T. (2016). Another adverse effect of vemurafenib: Gingival hyperplasia. The Journal of dermatology, 43(6), 706-707.

    Kaynak: medicana.com.tr profil sayfası

  29. Babacan, N. A., Eğilmez, H. R., Yücel, B., Parlak, I., Şeker, M. M., Kaçan, T., Bahceci A., Cıhan S., Akıncı B., Eriten B., Kılıçkap, S. (2016). The prognostic value of UHRF-1 and p53 in gastric cancer. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 22(1), 25.

    Kaynak: medicana.com.tr profil sayfası

  30. Babacan, N. A. (2016). Will we have a new ending for Irvin Yalom's novel? A medical oncologist view. Journal of Oncological Science, 2(1), 5-6.

    Kaynak: medicana.com.tr profil sayfası

  31. Kacan, T., Yucel, B., Bahar, S., Celasun, G., Seker, M. M., Babacan, N., Bahceci A., Kacan S., Kilickap, S. (2016). The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism. International Journal of Hematology and Oncology, 26(4), 136-144.

    Kaynak: medicana.com.tr profil sayfası

  32. Kacan, T., Nayir, E., Altun, A., Kilickap, S., Babacan, N. A., Ataseven, H., Kaya, T. (2016). Antitumor activity of sorafenib on colorectal cancer. Journal of Oncological Sciences, 2(2), 53-57.

    Kaynak: medicana.com.tr profil sayfası

  33. Kaya S, Aktas B, Tanrikulu Simsek E, Akif Ozturk M, Dede F, Kaya H, Ugurlu U, Ozgen Z, Koca S, Halil S, Hasanov R, Alan O, Akgul Babacan N, Ercelep O, Dane F, Gumus M, Yumuk F.(2017). Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer. J BUON. 2017 Sep-Oct;22(5):1191-1198.

    Kaynak: medicana.com.tr profil sayfası

  34. Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgul Babacan N, Dane F, Yumuk P Fulden (2018). Chordoma: a case series andreview of the literature. Journal of Medical Case Reports, 12:239.

    Kaynak: medicana.com.tr profil sayfası

  35. Bahceci A, Seker M M, Kacan T, Akgul Babacan N, Yucel B, Gedikli A. Sunitinib induced cytopenia in metastatic RCC (2018). Clin Med Rev Case Rep, 5:208.

    Kaynak: medicana.com.tr profil sayfası

  36. Alan, O., Ercelep, O., Telli, T. A., Tuylu, T. B., Önes, T., Bozkurtlar, E., NA Babacan ... & Kaya, S. (2018). P3. 16-48 Is Preoperative SUV (Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?. Journal of Thoracic Oncology, 13(10), S1020.

    Kaynak: medicana.com.tr profil sayfası

  37. Karadurmus N., Sendur M. A. N., Karaca B., Olmez O. F., Hacibekiroglu I., Coskun H. S., Degirmencioglu S., Kemal Y., Kilickap S., Sumbul A. T., Aydin B., Turna H., Kaplan M. A., Babacan N., Demirci U., Ata A., Erdem D., Ozet A., Abali H. (2018). Experience from Turkish centers participating in the early access program (EAP): preliminary real world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. Journal of Oncological Science, https://doi.org/10.1016/j.jons.2018.10.001

    Kaynak: medicana.com.tr profil sayfası

  38. Imeryuz, N., Atug, O., Kani, H. T., Alahdab, Y. O., Demirtas, C. O., Ozkan Gulsoy, H., O Ercelep, AE Atıcı, R Ergelen, IE Seven, NA Babacan... & Yemisci, I. (2019). Treatment of Hermansky-Pudlak syndrome Associated granulomatous colitis with anti-TNF agents: case series and review of literature.

    Kaynak: medicana.com.tr profil sayfası

  39. Babacan, Nalan A., and Tawee Tanvetyanon. Superimposed Clostridium Difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis (2019). Journal of Immunotherapy, 42(9), 350-353

    Kaynak: medicana.com.tr profil sayfası

  40. Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., VK Sondak, JL Messina, NA Babacan... & De Armas, L. (2019). Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine, 48, 178-190.

    Kaynak: medicana.com.tr profil sayfası

  41. Tuylu, T. B., Demircan, N. C., Arikan, R., Telli, T. A., Alan, O., Ercelep, O., F Dane, MA Ozturk, NA Babacan… - ... & Lacin, T. (2019). P2. 06-22 Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?. Journal of Thoracic Oncology, 14(10), S763.

    Kaynak: medicana.com.tr profil sayfası

  42. Ercelep, O., Alan, O., Sahin, D., Telli, T. A., Salva, H., Tuylu, T. B., NA Babacan... & Alkis, H. (2019). Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Clinical and Translational Oncology, 21(4), 499-504. doi: 10.1007/s12094-018-1949-6.

    Kaynak: medicana.com.tr profil sayfası

  43. Demircan, N. C., Dane, F., Ozturk, M. A., Babacan, N. A., Besiroglu, M., Kaya, S., ... & Alan, O. (2019). Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. Liver, 232, 64-4.

    Kaynak: medicana.com.tr profil sayfası

  44. Ercelep, Ö., Telli, T. A., Özkan, A. L. A. N., Hasanov, R., Şimşek, E. T., Babacan, N. A., ... & Yumuk, P. F. (2020). Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment? Single-Center Experience. Turkısh Journal Of Oncology, 1(3).

    Kaynak: medicana.com.tr profil sayfası

  45. Demircan, N. C., Alan, Ö., Başoğlu Tüylü, T., Akın Telli, T., Arıkan, R., Çiçek, F. C., R Ergelen, I Tinay, N Akgül Babacan ... & P F Yumuk. (2020). Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. Journal of Oncology Pharmacy Practice, 26(5), 1147-1155.

    Kaynak: medicana.com.tr profil sayfası

  46. Alan, O., Kuzhan, O., Koca, S., Telli, T. A., Basoglu, T., Ercelep, O., ... & Babacan, N. A. (2020). How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. Journal of Oncology Pharmacy Practice, 26(4), 1011-1018.

    Kaynak: medicana.com.tr profil sayfası

  47. Eroglu, Z., Eatrides, J., Naqvi, S. M. H., Kim, Y., Rich, J., Babacan, N. A., ... & Khushalani, N. I. (2020). Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell & Melanoma Research, 33(1), 86-95.

    Kaynak: medicana.com.tr profil sayfası

  48. Alan, O., Telli, T. A., Aktas, B., Koca, S., Ökten, I. N., Hasanov, R., MU Ugurlu, H Kaya, NA Babacan... & Kaya, S. (2020). Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?. World Journal of Surgical Oncology, 18(1), 1-9.

    Kaynak: medicana.com.tr profil sayfası

  49. Babacan, N. A., Pina, I. B., Signorelli, D., Prelaj, A., Garassino, M. C., & Tanvetyanon, T. (2020). Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clinical Lung Cancer, 21(5), e456-e463.

    Kaynak: medicana.com.tr profil sayfası

  50. Demirelli, B., Babacan, N. A., Ercelep, Ö., Öztürk, M. A., Kaya, S., Tanrıkulu, E., ... & Koca, S. (2020). Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutrition and Cancer, 1-9.

    Kaynak: medicana.com.tr profil sayfası